Sun Pharma
Last updated Jun 20, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
66%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Dermatology
- Acne
Highest priority development: FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
Regulatory precedent
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Sun Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Competitive pressure: Low
Portfolio impact: Moderate
Evidence coverage: 66%
Active Signals
2
Investigate Priority
0
Opportunity Score
34
Buyer Quality
3 · Low Priority
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 20, 2026Score 17FDA Accepts Supplement Application for Absorica by Sun Pharma
Dermatology · Acne
- MonitorJun 18, 2026Score 17FDA Accepts Supplement for ABSORICA LD by Sun Pharma
Dermatology · Acne
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Sun Pharma right now?
- Which regulatory precedents should Sun Pharma monitor in Dermatology and Acne?
- Which pipeline programs should Sun Pharma prioritize for competitive review?
- What signals require immediate investigation for Sun Pharma?
- Summarize the strategic implications of recent developments for Sun Pharma.
- Where is the greatest uncertainty in Sun Pharma's competitive positioning?